Observational analysis found T regulatory cells and tumor profile impact prognosis in young women with hormone receptor-positive breast cancer, suggesting risk stratification can aid treatment.
Background: The role of tumor-infiltrating lymphocytes (TILs) remains unclear in hormone receptor (HR)-positive/HER2-negative breast cancer, particularly in young patients, whose immune microenvironment could be altered by age-related host and tumor differences. Patients and methods: Patients with stage I-III HR-positive/HER2-negative tumors were identified from a prospective cohort study of breast cancer patients diagnosed at age ≤ 40 years. Multiplexed immunofluorescence and semiautomated quantitative software measured cytotoxic T, non-CD8 T, T regulatory, exhausted T, and PDL1+ cells in stroma and tumor. Univariate analyses assessed differences in clinicopathologic characteristics by high versus low immune infiltration, divided based on median. TIL subtypes were evaluated as a continuous variable per 10% increase in Cox regression analyses for invasive breast cancer-free survival (iBCFS), distant disease-free survival (DDFS), and overall survival (OS), adjusted for clinicopathologic parameters. Results: Among 390 patients, high immune infiltration was associated with increasing age, Black race, grade 3 tumors, and metaplastic or micropapillary histological subtypes. Over a median follow-up of 8 years, higher stromal and intratumoral non-CD8 T cell infiltration, T regulatory cell infiltration, and PDL1 expression was associated with improved iBCFS. Higher intratumoral non-CD8 T cell infiltration, T regulatory cell infiltration, and PDL1 expression was associated with improved DDFS; higher stromal PDL1 expression was also associated with improved DDFS. Higher intratumoral cytotoxic T cell infiltration and PDL1 expression was associated with improved OS. Conclusions: Characterization of immune subpopulations could help refine the prognostic value of TILs in young patients with HR-positive breast cancer, who may benefit from risk stratification for treatment individualization.
No takes yet. Share an insight, caveat, or question.
Tesch et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: